Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument
| Autor: | L. Antras, Maureen P. Neary, Mary O'Brien, Lei Chen, Mei Sheng Duh |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Pulmonary and Respiratory Medicine Adult Male medicine.medical_specialty Self-Assessment Palliative care Lung Neoplasms Patient Symptom Assessment in Lung Cancer instrument Antineoplastic Agents Severity of Illness Index Clinical trials Cronbach's alpha Internal medicine Multicenter trial Sickness Impact Profile Surveys and Questionnaires Severity of illness medicine Humans Multicenter Studies as Topic Psychometric validation Lung cancer Aged Randomized Controlled Trials as Topic Small cell lung cancer business.industry Palliative Care Construct validity Middle Aged medicine.disease Small Cell Lung Carcinoma Clinical trial Clinical Trials Phase III as Topic Physical therapy Topotecan Female Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(10) |
| ISSN: | 1556-1380 |
| Popis: | IntroductionLung cancer symptoms can be burdensome for patients with small cell lung cancer (SCLC). Patient Symptom Assessment in Lung Cancer (PSALC), a self-report scale for assessing SCLC symptom burden, was developed and validated previously using intravenous topotecan clinical trial data. This study cross-validates the PSALC using oral topotecan (OT) trial data.MethodsData were analyzed from a randomized, open-label, multicenter trial including 71 patients with relapsed SCLC receiving OT with best supportive care and 70 patients receiving best supportive care alone. PSALC and EQ-5D were administered at baseline and at 3-week intervals. Internal consistency, reliability, construct validity, and responsiveness were evaluated.ResultsOnly one factor was indicated in factor analysis, hence PSALC total score (PSALC-TS) was used for psychometric analysis. Internal consistency was supported by Cronbach's alpha of 0.78. Construct validity was supported by significant associations of higher PSALC-TS (higher symptom burden) with worse Eastern Cooperative Oncology Group performance status and by correlations of PSALC-TS with EQ-5D utility index and visual analog scale score (all p < 0.001). Reliability was supported by intraclass correlation coefficient of 0.68 (using PSALC-TS before clinical status change) and concordance correlation coefficient of 0.69 (using PSALC-TS at baseline and before first visit). PSALC-TS was responsive to clinical status change from baseline to tumor response (responsiveness statistic = −0.99) and to tumor progression (responsiveness statistic = 0.94).ConclusionsConsistent with prior psychometric results, this cross-validation study using OT trial data showed acceptable validity, reliability, and responsiveness of the PSALC scale, further supporting its use to measure symptom burden in previously treated SCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|